Controlling the Cost Spent on Expensive Biologic Agents- an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients
Abstract
Authors
W Kievit N van Herwaarden F van den Hoogen R van Vollenhoven H Bijlsma B van den Bemt A van der Maas A den Broeder